Changchun BCHT Biotechnology Co.

SHSE:688276 Stock Report

Market Cap: CN¥9.2b

Changchun BCHT Biotechnology Management

Management criteria checks 2/4

Changchun BCHT Biotechnology's CEO is Wei Kong, appointed in Jan 2004, has a tenure of 21.08 years. directly owns 25.25% of the company’s shares, worth CN¥2.32B. The average tenure of the management team and the board of directors is 6 years and 4.9 years respectively.

Key information

Wei Kong

Chief executive officer

CN¥4.2m

Total compensation

CEO salary percentagen/a
CEO tenure21.1yrs
CEO ownership25.2%
Management average tenure6yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

Changchun BCHT Biotechnology (SHSE:688276) Seems To Use Debt Quite Sensibly

Jan 03
Changchun BCHT Biotechnology (SHSE:688276) Seems To Use Debt Quite Sensibly

Market Might Still Lack Some Conviction On Changchun BCHT Biotechnology Co. (SHSE:688276) Even After 36% Share Price Boost

Oct 07
Market Might Still Lack Some Conviction On Changchun BCHT Biotechnology Co. (SHSE:688276) Even After 36% Share Price Boost

Analysts Just Slashed Their Changchun BCHT Biotechnology Co. (SHSE:688276) EPS Numbers

Aug 22
Analysts Just Slashed Their Changchun BCHT Biotechnology Co. (SHSE:688276) EPS Numbers

Changchun BCHT Biotechnology Co. (SHSE:688276) Doing What It Can To Lift Shares

Jul 28
Changchun BCHT Biotechnology Co. (SHSE:688276) Doing What It Can To Lift Shares

Is Changchun BCHT Biotechnology (SHSE:688276) Using Too Much Debt?

Jun 19
Is Changchun BCHT Biotechnology (SHSE:688276) Using Too Much Debt?

Changchun BCHT Biotechnology Co. (SHSE:688276) Shares Slammed 25% But Getting In Cheap Might Be Difficult Regardless

Apr 16
Changchun BCHT Biotechnology Co. (SHSE:688276) Shares Slammed 25% But Getting In Cheap Might Be Difficult Regardless

We Think That There Are Issues Underlying Changchun BCHT Biotechnology's (SHSE:688276) Earnings

Mar 30
We Think That There Are Issues Underlying Changchun BCHT Biotechnology's (SHSE:688276) Earnings

CEO

Wei Kong (59 yo)

21.1yrs

Tenure

CN¥4,195,400

Compensation

Mr. Kong Wei serves as General Manager at Changchun BCHT Biotechnology Co. from 2004 and has been its Director from February 21, 2019.

Leadership Team

NamePositionTenureCompensationOwnership
Wei Kong
GM & Director21.1yrsCN¥4.20m25.25%
CN¥ 2.3b
Zhaofeng Meng
Chief Financial Officer6yrsCN¥2.13m0.0080%
CN¥ 733.1k
Chunlai Jiang
Executive Deputy GM & Directorno dataCN¥3.39m0.31%
CN¥ 28.4m
Zhe Zhang
Board Secretary2.4yrsCN¥1.42m0.0036%
CN¥ 333.5k
Bing Yu
Deputy General Manager6yrsCN¥3.47m0.24%
CN¥ 22.3m
Dawei Liu
Deputy General Managerno dataCN¥2.72m0.17%
CN¥ 16.0m
Xiaohui Chen
Chief Operating Specialistno datano datano data
Wei Wei
Deputy General Manager6yrsCN¥801.80k0.27%
CN¥ 25.2m
Changlin Zhu
Core Technical Staffno datano datano data

6.0yrs

Average Tenure

53yo

Average Age

Experienced Management: 688276's management team is seasoned and experienced (6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Wei Kong
GM & Director6yrsCN¥4.20m25.25%
CN¥ 2.3b
Chunlai Jiang
Executive Deputy GM & Director4.9yrsCN¥3.39m0.31%
CN¥ 28.4m
Bainian Fu
Independent Director4.7yrsCN¥72.00kno data
Xiufeng Li
Director6yrsno datano data
De Shen Zhang
Supervisor6yrsno datano data
Xing Gong Zhu
Director3.5yrsno datano data
Ji Ma
Chairman6yrsno datano data
Yuntao Jiang
Director6yrsno datano data
Jing Liu
Independent Director4.7yrsCN¥72.00kno data
Dayong Xu
Independent Director4.7yrsCN¥72.00kno data
Daqiang Feng
Chairman of the Supervisory Board4.9yrsno data0.39%
CN¥ 35.7m
Yang Yang
Employee Supervisor4.7yrsno datano data

4.9yrs

Average Tenure

58.5yo

Average Age

Experienced Board: 688276's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/05 12:46
End of Day Share Price 2025/02/05 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Changchun BCHT Biotechnology Co. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hangci ZhengChina International Capital Corporation Limited
Yizheng YangChina International Capital Corporation Limited
Sophia ZhangChina Stock Investment Research Co. Ltd. (GZ500..com)